Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

Inclusion Criteria: * Aged 12 years and above. * Written informed consent signed by participant and, in the case of minors, parents/caregivers. * Agree to comply with study procedures, including provision of two stool samples at the beginning (screening) and at follow-up assessment 14-21 days after treatment. * Having at least two slides of the quadruple Kato-Katz thick smears positive for Trichuris incognita and infection intensities of at least 48 eggs per gram (EPG). * Willing to be examined by a study physician prior to treatment. Exclusion Criteria: * Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38 °C, severe anemia (Hb below 80g/l) upon initial clinical assessment etc. * History of severe acute or unmanaged severe chronic disease (i.e., condition is not as therapeutically controlled as necessary). * Positive malaria rapid diagnostic test (RDT) and temperature ≥ 38 °C. * Abnormal liver and renal function assessed by biochemical blood-based analyses. * Recent use of anthelmintic drugs (in the 4 weeks before treatment). * Known allergy to study medications and formulations (i.e. albendazole and emodepside). * Prescribed or taking medication with known contraindication to or interaction with study drugs. * Participating in other clinical trials during the study period. * Pregnancy or breastfeeding.